WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Disclosures for additional planners can be found here.

Faculty

Rikke Borg, MD, PhD

Associate Professor
Department of Clinical Medicine
Nephrology Section
Clinical Research Unit
Zealand University Hospital
Roskilde, Denmark

Disclosures

Rikke Borg, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Mundipharma; Vifor Pharma
Speaker or member of speakers bureau for: AstraZeneca; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Mundipharma
Research funding from: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Novo Nordisk

Naresh Kanumilli, MBBS, MRCGP

Northenden Group Practice
Manchester, United Kingdom

Disclosures

Naresh Kanumilli, MBBS, MRCGP, has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Liva Health; Novo Nordisk
Speaker or member of speakers bureau for: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.

Editor

Rita Moreira Da Silva, PhD, PharmD

Medical Education Director, WebMD Global, LLC

Disclosures

Rita Moreira Da Silva, PhD, PharmD, has no relevant financial relationships.

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CPD

Safeguarding the CKD Patient With or Without Diabetes in Primary Care: Quick Questions, Rapid Replies

Authors: Rikke Borg, MD, PhD; Naresh Kanumilli, MBBS, MRCGP
CPD Released: 3/27/2023
Valid for credit through: 3/27/2024

Start Activity

Credits Available

Non-US Physicians - maximum of 0.25 CPD

You Are Eligible For
- Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US primary care physicians, diabetologists/endocrinologists, and nephrologists (excluding UK and Ireland).

The goal of this activity is for learners to be better able to understand the importance and practicalities of early chronic kidney disease (CKD) detection in primary care as well as the benefits of renoprotective therapies like sodium glucose co-transporter 2 (SGLT2) inhibitors in CKD management.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Urgent need for the early identification of patients with CKD
Have greater competence related to
- Using SGLT2 inhibitors with proven kidney benefit in a broad range of patients with CKD

Disclosures

Disclosures for additional planners can be found here.

Faculty

Rikke Borg, MD, PhD

Associate Professor
Department of Clinical Medicine
Nephrology Section
Clinical Research Unit
Zealand University Hospital
Roskilde, Denmark

Disclosures

Rikke Borg, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Mundipharma; Vifor Pharma
Speaker or member of speakers bureau for: AstraZeneca; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Mundipharma
Research funding from: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Novo Nordisk

Naresh Kanumilli, MBBS, MRCGP

Northenden Group Practice
Manchester, United Kingdom

Disclosures

Naresh Kanumilli, MBBS, MRCGP, has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Liva Health; Novo Nordisk
Speaker or member of speakers bureau for: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.

Editor

Rita Moreira Da Silva, PhD, PharmD

Medical Education Director, WebMD Global, LLC

Disclosures

Rita Moreira Da Silva, PhD, PharmD, has no relevant financial relationships.

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.